Immuno-oncology partnership announced
12 Feb 2016 by qwqcdhhcbc.d qwqcdhhcbc.d
Kymab and the University of Texas have announced a strategic cancer drug discovery and development alliance
Kymab and the University of Texas have announced a strategic cancer drug discovery and development alliance.
The alliance will aim to discover and develop new human antibodies to treat different forms of cancer.
David Chiswell, Kymab CEO, said: “Together, Kymab and MD Anderson bring power and skills to a partnership committed to efficiency and speed in delivering novel immunotherapies through the use of world-class science. Immuno-oncology is an exceptionally promising field of research and a key focus for Kymab.”
Kymab and the University’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) will work together utilising both the in house antibody platform, Kymouse and ORBIT’s clinical datasets and infrastructure to develop products. The five year agreement will see monoclonal antibodies developed as well as biomarkers identified for recognising responder populations.
Kymouse – produced by Kymab – produces antibodies with drug like properties and can identify high-quality molecules than can be explored as new therapeutic possibilities.
Dr Carlo Toniatti, executive director of ORBIT said: “These are exciting times for the development of monoclonal antibodies for cancer immunotherapy. This alliance presents a great opportunity to leverage our translational and clinical expertise, and develop innovative antibody drugs vital to helping patients in their fight against cancer."
